Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Cash from Investing Activities (2018 - 2019)

Endonovo Therapeutics has reported Cash from Investing Activities over the past 4 years, most recently at -$723.0 for Q3 2019.

  • Quarterly results put Cash from Investing Activities at -$723.0 for Q3 2019, changed N/A from a year ago — trailing twelve months through Dec 2019 was -$723.0 (up 91.94% YoY), and the annual figure for FY2019 was -$2594.0, up 71.08%.
  • Cash from Investing Activities for Q3 2019 was -$723.0 at Endonovo Therapeutics, up from -$8969.0 in the prior quarter.
  • Over the last five years, Cash from Investing Activities for ENDV hit a ceiling of -$723.0 in Q3 2019 and a floor of -$8969.0 in Q1 2018.